Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Early Hum Dev ; 150: 105186, 2020 11.
Artigo em Inglês | MEDLINE | ID: mdl-32958330

RESUMO

There is a wide differential diagnosis of early onset respiratory distress especially in term babies, and interstitial lung disease (chILD) is a rare but important consideration in this context. chILD manifesting immediately after birth is usually related to mutations in surfactant protein genes, or conditions related to the Congenital Acinar Dysplasia -Alveolar capillary dysplasia - Congenital Alveolar Dysplasia (CAD-ACD) spectrum. There is currently no specific treatment for these conditions, and management is supportive. Prognosis is very poor in most of these babies if onset is early, with relentless respiratory deterioration unless transplanted. Ideally, the diagnosis is made on genetic analysis, but this may be time-consuming and complex in CAD-ACD spectrum, so lung biopsy may be needed to avoid prolonged and futile treatment being instituted. Milder forms with prolonged survival have been reported. Early onset, less severe chILD is usually related to neuroendocrine cell hyperplasia of infancy (NEHI), pulmonary interstitial glycogenosis (PIG) and less severe disorders of surfactant proteins. PIG and NEHI are not specific entities, but are pulmonary dysmaturity syndromes, and there may be a number of underlying genetic and other cause. If the child is stable and thriving, many will not be subject to lung biopsy, and slow improvement and weaning of supplemental oxygen can be anticipated. Where possible, a precise genetic diagnosis should be made in early onset cHILD allow for genetic counselling. chILD survivors and their families have complex respiratory and other needs, and co-ordinated, multi-disciplinary support in the community is essential.


Assuntos
Doenças do Recém-Nascido/diagnóstico , Doenças Pulmonares Intersticiais/diagnóstico , Diagnóstico Diferencial , Testes Genéticos , Humanos , Recém-Nascido , Doenças do Recém-Nascido/genética , Doenças do Recém-Nascido/terapia , Doenças Pulmonares Intersticiais/genética , Doenças Pulmonares Intersticiais/terapia , Mutação
2.
BMC Pulm Med ; 19(1): 185, 2019 Oct 24.
Artigo em Inglês | MEDLINE | ID: mdl-31651292

RESUMO

BACKGROUND: Diffuse alveolar haemorrhage (DAH) is characterized by the diffuse accumulation of red blood cells within the alveoli, presence of ground glass opacities and/or consolidation on computed tomography (CT). Aside from identifiable non-immune causes, DAH is classically subdivided into idiopathic (idiopathic pulmonary haemosiderosis, IPH) and autoimmune DAH. Here we describe three cases presenting with recurrent pulmonary haemorrhage, initially classified as IPH, who, several years after first presentation, develop anti myeloperoxidase antibodies (MPO) positivity, emphysema on CT and, in one case, renal involvement. CASE PRESENTATION: Patient 1 was diagnosed with IPH aged 14. Her disease remained poorly controlled despite immunosuppression, although ANCA remained negative over the years. Nineteen years from initial presentation, she developed MPO-ANCA positive antibodies and mild renal impairment. She was treated with Rituximab with good response. From first presentation, the chest CT was consistently characterized by diffuse ground-glass opacities and interlobular septal thickening. Ten years later, cystic opacities consistent with emphysema, with a striking peribronchovascular distribution, developed. Patient 2 was diagnosed with IPH aged 32. He was treated with corticosteroids and methotrexate, with fluctuating response. At 11 years from initial presentation, MPO-ANCA positivity was identified, and emphysema with a peribronchovascular distribution was observed on CT, with subsequent significant increase in extent. Patient 3 was diagnosed with IPH at the age of seven, and had recurrent episodes of haemoptysis of varying degree of severity, treated with intermittent courses of corticosteroids until age 11, when he was intubated due to severe DAH. Eight years after the diagnosis emphysematous changes were noted on CT and MPO-ANCA positivity developed for the first time 11 years after initial diagnosis. CONCLUSIONS: We believe these three cases highlight: 1) the possibility of development of ANCA positivity several years down the line from first DAH presentation 2) the possibility that DAH may lead to cystic/emphysematous changes with peribronchovascular distribution on CT. Moreover, the need for ongoing immunosuppressive treatment and the development of emphysema, emphasize a possible role played by autoimmune phenomena, even when DAH is initially diagnosed as "idiopathic". Further studies are required to better understand the relationship between DAH, ANCA positivity and development of emphysema.


Assuntos
Anticorpos Anticitoplasma de Neutrófilos/sangue , Glucocorticoides/administração & dosagem , Hemoptise , Metotrexato/administração & dosagem , Peroxidase/imunologia , Enfisema Pulmonar , Rituximab/administração & dosagem , Adolescente , Adulto , Criança , Diagnóstico Diferencial , Feminino , Hemoptise/diagnóstico , Hemoptise/etiologia , Hemoptise/imunologia , Hemossiderose/diagnóstico , Humanos , Imunossupressores/administração & dosagem , Pulmão/diagnóstico por imagem , Pneumopatias/diagnóstico , Masculino , Administração dos Cuidados ao Paciente , Enfisema Pulmonar/complicações , Enfisema Pulmonar/diagnóstico , Enfisema Pulmonar/imunologia , Enfisema Pulmonar/fisiopatologia , Insuficiência Renal/diagnóstico , Insuficiência Renal/imunologia , Tomografia Computadorizada por Raios X/métodos , Hemossiderose Pulmonar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...